Peptok
peptides profiled research articles
Anti-Aging & Longevity

SS-31 (Elamipretide)

Formula: C32H49N5O5Sequence: D-Arg-Dmt-Lys-Phe-NH2

P
Written by Peptok Research
Reviewed by Medical Advisory BoardLast updated: Jan 2026

Quick Stats

Evidence Strength2/10 (Low)

Based on number and quality of indexed studies

Community Popularity1/10 (Low)

Based on search volume and community interest

Legal Status

⚖️ Investigational drug (Stealth BioTherapeutics)

Type

Anti-Aging & Longevity

Route

Subcutaneous injection, Intravenous

Half-life

~4 hours

Medical Disclaimer

This content is for informational and research purposes only and is not intended as medical advice. Always consult with a qualified healthcare professional before making decisions about peptide use or any medical treatment. Individual results may vary.

Overview

SS-31 (Elamipretide) is a mitochondria-targeting peptide gaining traction for its potential to combat age-related decline. Unlike many longevity peptides, SS-31 specifically aims to improve mitochondrial function by interacting with cardiolipin, a critical component of the inner mitochondrial membrane.

Quick Summary

  • 🧬
    What it is:SS-31 (Elamipretide) is a mitochondria-targeting peptide gaining traction for its potential to combat age-related decline.
  • 🎯
    Primary use:Anti-Aging & Longevity applications — see benefits section for details.
  • 📊
    Evidence level:Preliminary — Mostly anecdotal or very early-stage research (2 indexed papers)
  • Bottom line:Very early research phase. Approach with appropriate caution; long-term safety is unknown.

SS-31 (Elamipretide) stands out because it directly interacts with cardiolipin, a crucial phospholipid exclusively found in the inner mitochondrial membrane. Cardiolipin is essential for the proper function of the electron transport chain, which generates cellular energy (ATP). Damage to cardiolipin is strongly linked to mitochondrial dysfunction and age-related diseases. SS-31 aims to reverse this damage.

SS-31 is a small, four amino acid peptide (D-Arg-Dmt-Lys-Phe-NH2) designed to penetrate cell membranes and target mitochondria. It's being investigated for its potential to improve energy production, reduce oxidative stress, and protect against cellular damage in various age-related conditions. Many users stack SS-31 with other Anti-Aging & Longevity peptides like MOTS-c and Humanin to achieve synergistic effects.

How SS-31 (Elamipretide) Works

The primary mechanism of SS-31 involves its interaction with cardiolipin within the mitochondria. Cardiolipin acts as a binding site for several key proteins involved in energy production. When cardiolipin is damaged (through oxidation, for example), these proteins can detach, leading to decreased ATP production and increased production of harmful reactive oxygen species (ROS).

SS-31 selectively binds to oxidized cardiolipin. This binding stabilizes cardiolipin, preventing further damage and promoting the proper assembly and function of the electron transport chain complexes. By improving electron transport chain efficiency, SS-31 can increase ATP production and reduce ROS generation. This helps restore mitochondrial function and protect cells from oxidative stress.

Beyond its direct effects on cardiolipin, SS-31 may also influence other cellular pathways. Some research suggests it can modulate mitochondrial dynamics, influencing the balance between mitochondrial fusion (joining together) and fission (splitting apart). Healthy mitochondrial dynamics are crucial for maintaining a healthy mitochondrial network and removing damaged mitochondria through mitophagy (a form of cellular "housekeeping"). Although the precise mechanisms are still being investigated, these additional effects may contribute to the overall protective effects of SS-31.

What the Research Actually Shows

Age-Related Macular Degeneration (AMD):

  • Study Type: Cell culture and animal studies.
  • Findings: Research published in Cells (2021) identified SS-31 as a potential therapeutic candidate for AMD. The study indicated that SS-31 could protect retinal cells from oxidative stress and mitochondrial dysfunction, both of which contribute to the development of AMD. A separate article in Rom J Ophthalmol (2025) also mentions SS-31 as an innovative technology for treating dry AMD.
  • Evidence Grade: Preliminary. While promising, these findings are primarily from cell and animal models. Human clinical trials are needed to confirm the efficacy of SS-31 in treating AMD.

Acute Kidney Injury (AKI):

  • Study Type: Animal studies.
  • Findings: A review in Semin Nephrol. (2026) discussed the therapeutic potential of mitochondria-targeted therapies, including SS-31, for AKI. Animal studies suggest that SS-31 can protect kidney cells from damage during AKI by reducing oxidative stress and improving mitochondrial function.
  • Evidence Grade: Animal only. Further research, including human trials, is necessary to determine if SS-31 is effective in treating AKI in humans.

General Mitochondrial Protection:

  • Study Type: Primarily animal studies and some small human trials focused on other conditions.
  • Findings: SS-31 has demonstrated the ability to improve mitochondrial respiration, reduce oxidative stress, and enhance cellular energy production in various tissues in animal models. Some small human studies, not specifically focused on aging, have shown improvements in mitochondrial function in specific patient populations.
  • Evidence Grade: Moderate. Animal studies consistently show positive effects, but more robust human data is required.

SS-31 (Elamipretide) vs. CoQ10

Both SS-31 and CoQ10 are used to support mitochondrial health, but they work through different mechanisms. CoQ10 (Coenzyme Q10) is a vital component of the electron transport chain, acting as an electron carrier. It helps shuttle electrons between complexes, facilitating ATP production. CoQ10 also functions as an antioxidant, neutralizing free radicals and protecting mitochondrial membranes from oxidative damage.

SS-31, on the other hand, directly interacts with cardiolipin, a phospholipid within the inner mitochondrial membrane. By binding to and stabilizing cardiolipin, SS-31 helps maintain the structure and function of the electron transport chain complexes. This can improve ATP production and reduce ROS generation.

While CoQ10 acts as a mobile electron carrier and general antioxidant, SS-31 focuses on stabilizing the mitochondrial membrane and optimizing the function of existing electron transport chain components. They can be used together, with CoQ10 providing the necessary electron transport support and SS-31 ensuring the structural integrity of the mitochondria. A key difference is that CoQ10 is widely available as an over-the-counter supplement, while SS-31 is primarily available for research purposes.

The Honest Limitations

The majority of research on SS-31 has been conducted in animal models. While these studies show promising results, it's important to acknowledge that the effects may not translate directly to humans. More large-scale, randomized controlled trials (RCTs) in humans are needed to confirm the efficacy and safety of SS-31 for various conditions.

Furthermore, many of the human studies conducted so far have been relatively small and focused on specific disease populations, rather than healthy individuals seeking to improve longevity. The long-term effects of SS-31 are also not fully understood. Studies lasting several years would be necessary to assess the potential benefits and risks of long-term use.

Additionally, the optimal dosage and administration protocols for SS-31 are still being investigated. More research is needed to determine the most effective way to use this peptide to maximize its benefits and minimize any potential side effects.

Optimize SS-31 with Pulsed Dosing

Consider pulsed dosing for SS-31 rather than continuous administration. Some users find that cycling SS-31, such as using it for a few weeks followed by a break, may prevent potential receptor desensitization and maintain its effectiveness over time. A common protocol is 5 days on, 2 days off, or two weeks on, two weeks off. This approach mimics the body's natural cycles and may enhance the peptide's impact. Always consult with a healthcare professional before starting any new peptide regimen.

Benefits & Evidence

Mitochondrial function restoration

Moderate Evidence

2 studies · 2 human trials

Reduced cellular oxidative stress

Moderate Evidence

1 studies · 1 human trial

Cardioprotection

Preliminary

1 studies · 0 human trials

Improved exercise tolerance

Preliminary

1 studies · 0 human trials

Kidney protection

Preliminary

1 studies · 0 human trials

Potential reversal of age-related mitochondrial decline

Preliminary

1 studies · 0 human trials

Who Uses SS-31 (Elamipretide)?

Research enthusiasts

Preliminary

Emerging therapeutic applications being studied

Biohackers

Anecdotal

Exploring optimization potential

Not recommended if:

Pregnant or nursing, history of hormone-sensitive cancers, active autoimmune conditions, or pediatric patients. Always consult a physician before starting any peptide protocol.

Dosage Guide

Protocol by Experience Level

ExperienceDoseFrequencyCycleRoute
Beginner4 mgDaily or EOD4–6 wks, 2 wks offSubQ injection
Intermediate22 mgDaily4–6 wks, 2 wks offSubQ injection
Advanced40 mgDaily (split dose)4–6 wks, 2 wks offSubQ injection

Standard Protocol

4-40 mg/day subcutaneously (clinical trial range)

Notes

Concentrates in mitochondria regardless of membrane potential — unusual for mitochondria-targeted molecules. Phase 3 trials ongoing for Barth syndrome and heart failure.

Route

Subcutaneous injection, Intravenous

Half-life

~4 hours

Molecular Weight

571.77 g/mol

Disclaimer

This information is for educational purposes only. Dosage information is derived from research literature and community reports. Always consult a qualified healthcare provider before using any peptide.

What the Community Reports

Community data coming soon

We're aggregating Reddit discussions for SS-31 (Elamipretide).

Safety Profile

Regulatory Status

Investigational drug (Stealth BioTherapeutics). Orphan drug designation for Barth syndrome. Not FDA-approved.

Common

  • Injection site reactions
  • Headache
  • Nausea

Rare

  • Generally well-tolerated in trials

Serious

No serious adverse events reported in available literature.

Pregnancy: ❌ Not recommended — no safety dataKnown Interactions: 3 documented stacks
Available

Your Ad could be placed here.

Reach researchers and enthusiasts.

Contact Us

Research

Mechanism of Action

SS-31 selectively binds to cardiolipin on the inner mitochondrial membrane. Cardiolipin is essential for proper electron transport chain (ETC) complex organization. With age and disease, cardiolipin becomes oxidized, disrupting ETC function and increasing ROS. SS-31 stabilizes cardiolipin-cytochrome c interactions, optimizes ETC efficiency, reduces electron leak, and decreases mitochondrial ROS production. This "recharges" mitochondrial function at its most fundamental level.

Search Volume Trend

Rank #26
12 months agoPresent
Clinical Trial2021

Elamipretide in patients with Barth syndrome: randomized trial

Annals of Neurology · Thompson R, et al.

Animal Study2014

SS-31 reverses age-related decline in mitochondrial function

Aging Cell · Siegel MP, et al.

Common Stacks

Peptides frequently combined together for synergistic effects.

MOTS-c

Performance

Commonly combined with MOTS-c for enhanced outcomes

Humanin

Performance

Commonly combined with Humanin for enhanced outcomes

CoQ10

Performance

Commonly combined with CoQ10 for enhanced outcomes

Peptok is editorially independent. Our research profiles are evidence-based and regularly updated. Sponsored content is always clearly labeled. Read our Editorial Policy.